These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30131378)

  • 1. Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
    Galliverti G; Tichet M; Domingos-Pereira S; Hauert S; Nardelli-Haefliger D; Swartz MA; Hanahan D; Wullschleger S
    Cancer Immunol Res; 2018 Nov; 6(11):1301-1313. PubMed ID: 30131378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.
    Domingos-Pereira S; Roh V; Hiou-Feige A; Galliverti G; Simon C; Tolstonog GV; Nardelli-Haefliger D
    Oncoimmunology; 2021 Apr; 10(1):1912473. PubMed ID: 33907631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.
    Domingos-Pereira S; Galliverti G; Hanahan D; Nardelli-Haefliger D
    J Immunother Cancer; 2019 May; 7(1):122. PubMed ID: 31060612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
    Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
    Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
    Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
    Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A therapeutic HPV16 E7 vaccine in combination with active anti-FGF-2 immunization synergistically elicits robust antitumor immunity in mice.
    Xie H; Shu C; Bai H; Sun P; Liu H; Qi J; Li S; Ye C; Gao F; Yuan M; Chen Y; Pan M; Yang X; Ma Y
    Nanomedicine; 2020 Oct; 29():102254. PubMed ID: 32615335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employing ATP as a New Adjuvant Promotes the Induction of Robust Antitumor Cellular Immunity by a PLGA Nanoparticle Vaccine.
    Zhang Q; Huang W; Yuan M; Li W; Hua L; Yang Z; Gao F; Li S; Ye C; Chen Y; He J; Sun W; Yang X; Bai H; Ma Y
    ACS Appl Mater Interfaces; 2020 Dec; 12(49):54399-54414. PubMed ID: 33215918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Immunity Induced by Genetic Immunization with Chitosan Nanoparticle Formulated Adjuvanted for HPV-16 E7 DNA Vaccine.
    Tahamtan A; Barati M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
    Iran J Immunol; 2018 Dec; 15(4):269-280. PubMed ID: 30593741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
    Bartkowiak T; Singh S; Yang G; Galvan G; Haria D; Ai M; Allison JP; Sastry KJ; Curran MA
    Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5290-9. PubMed ID: 26351680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells.
    Chen Z; Ozbun L; Chong N; Wallecha A; Berzofsky JA; Khleif SN
    Cancer Immunol Res; 2014 Sep; 2(9):911-22. PubMed ID: 24872025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
    Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
    Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.